Skip to main content

Advertisement

Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance

Fig. 2

Comparison of OS and DFS between patients with low or high gene expression with statistical significance in univariate analysis. a, b The median OS and DFS of patients with low or high MECOM expression were 30 ± 4.7 months versus 11 ± 1.8 months (P < 0.001), and 39 ± 8.1 months versus 14 ± 3.8 months (P = 0.017), respectively. c, d The median OS and DFS of patients with low or high MEIS1 expression were 34 ± 5.3 months versus 11.5 ± 1.7 months (P < 0.001), and 39 ± 8.7 months versus 14.5 ± 4.1 months (P = 0.016), respectively. e, f The median OS and DFS of patients with low or high SPI1 expression were 25 ± 5.4 months versus 14 ± 2.1 months (P = 0.008), and 36 ± 7.7 months versus 21 ± 5.3 months (P = 0.039), respectively. g, h The median OS and DFS of patients with low or high WT1 expression were 22 ± 4.2 months versus 15 ± 2.3 months (P = 0.096) and 39 ± 14.4 months versus 20 ± 5.9 months (P = 0.098), respectively. i, j Patients with low expression of both MECOM and MEIS1 were compared to those with either or both high expression of MECOM and MEIS1. The median OS were 56.5 ± 17.5, 14 ± 2.6 and 8 ± 2.2 months (P < 0.001). The median DFS were 46 ± 8.2, 27.5 ± 7.9 and 12 ± 1.7 months (P = 0.013). The hazard ratios (HR) of high MECOM or MEIS1 for OS and DFS were 2.076 (95% CI 1.455–2.962) and 1.379 (95% CI 0.893–2.131), respectively, while the HR of High MECOM and High MEIS1 were 3.040 (95% CI 2.088–4.427) and 2.024 (95% CI 1.265–3.238), respectively. k, l The OS and DFS were compared in a subgroup of patients with low expression of both MECOM and MEIS1. The median OS and DFS of patients with low or high WT1 expression were NR versus 18 ± 2.4 months (P = 0.002), and 77 ± 32.7 months versus 18 ± 4.5 months (P = 0.002), respectively

Back to article page